---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report. Covers Cost-effectiveness evidence and Budget impact model. 42 evidence topics quoted from 28 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary

No budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found, and no price for it has been published. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then”, and its presentation describes first-line recurrent or metastatic HPV-negative HNSCC as “a global commercial opportunity of ~$5B+ annually by 2030”. Three published U.S. payer models address first-line comparators. Borse et al. (2022) used a three-state partitioned-survival model over 20 years with 3% annual discounting: pembrolizumab monotherapy was dominant versus the EXTREME regimen in the CPS ≥1 population, and pembrolizumab combination therapy was cost-effective versus EXTREME at $1769/QALY in the overall population. In the Markov model of She et al. (2022), pembrolizumab plus chemotherapy versus cetuximab plus chemotherapy yielded ICERs of $147876.14, $134237.84, and $153660.78 per QALY in the total, CPS ≥1, and CPS ≥20 populations. Ye et al. (2024), using a 15-year three-state partitioned survival model, found the EXTREME regimen cost-effective compared with nivolumab plus ipilimumab at a willingness-to-pay threshold of $150,000/QALY. None of these models includes ficerafusp alfa.

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm); [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4); [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/); [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/); [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

<a id="topic-4.1-2"></a>

#### Budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa

No evidence found.

<a id="topic-4.1-3"></a>

#### Company statements on pricing and launch timing of ficerafusp alfa

> “In November 2026, we announced that FORTIFI-HN01 reached substantial enrollment to enable an interim analysis in mid-2027 to support a potential approval and U.S. launch in 2028.”
> “Even if ficerafusp alfa achieves marketing approval, it may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-4.1-4"></a>

#### Company estimate of the market for first-line treatment of recurrent or metastatic HPV-negative disease

> “1L R/M HPV-negative HNSCC represents a global commercial opportunity of ~$5B+ annually by 2030 in a setting of profound unmet need”
> “A $5B+ annual global market that FICERA is built to lead, and to grow”
> “projected annual global HNSCC sales by 2030”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-4.1-5"></a>

#### Cost-effectiveness of first-line pembrolizumab regimens from a United States payer perspective

> “Using public drug prices, from a US payer perspective, we evaluated the cost-effectiveness of each pembrolizumab regimen vs. cetuximab + platinum+5-FU (EXTREME regimen, trial comparator), cisplatin + docetaxel + cetuximab (TPEx regimen), cisplatin + paclitaxel, and platinum+5-FU.”
> “First-line pembrolizumab monotherapy in patients with CPS ≥1, and pembrolizumab combination therapy in the overall R/M HNSCC population is cost-effective from the perspective of the US payers.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

<a id="topic-4.1-6"></a>

#### Cost-effectiveness of first-line pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy

> “First-line treatment with pembrolizumab or pembrolizumab plus chemotherapy are cost-effective strategies compared with cetuximab plus chemotherapy when the value of willingness-to-pay (WTP) was $150000 per QALY for the total and PD-L1 CPS ≥ 1 populations with recurrent or metastatic HNSCC.”

Source: [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/)

<a id="topic-4.1-7"></a>

#### Cost-effectiveness of first-line nivolumab plus ipilimumab versus the EXTREME regimen

> “The EXTREME regimen is cost-effective compared with nivolumab plus ipilimumab for all randomly assigned populations with R/M SCCHN at a WTP threshold of $150,000/QALY from the payer's perspective in the United States.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

Additional sources: [Fraslin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40848743/); [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12083786/)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

<a id="topic-4.2.1-1"></a>

##### Budget impact model of ficerafusp alfa: approach and framework

No evidence found.

<a id="topic-4.2.1-2"></a>

##### Good-practice framework for budget impact analysis

> “The key elements of a BIA include estimating the size of the eligible population, the current mix of treatments and the expected mix after the introduction of the new intervention, the cost of the treatment mixes, and any changes expected in condition-related costs.”
> “Where possible, the BIA calculations should be performed by using a simple cost calculator approach because of its ease of use for budget holders.”
> “In instances, however, in which the changes in eligible population size, disease severity mix, or treatment patterns cannot be credibly captured by using the cost calculator approach, a cohort or patient-level condition-specific model may be used to estimate the budget impact of the new intervention, accounting appropriately for those entering and leaving the eligible population over time.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “Finally, the Task Force recommends that the analyst use the simplest design that will generate credible and transparent estimates.”
> “The model should be consistent with that used for the CEA with regard to clinical and economic assumptions.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.1-3"></a>

##### Model structures used in economic evaluations of first-line regimens for recurrent or metastatic disease

> “A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting.”
> “Time-on-treatment was derived from KEYNOTE-048 or approximated using network meta-analysis progression-free survival estimates.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

> “A Markov structure was conducted to evaluate the cost and effectiveness of pembrolizumab monotherapy or pembrolizumab plus chemotherapy vs. cetuximab plus chemotherapy in the first-line treatment of recurrent or metastatic HNSCC from the United States payer's perspective.”

Source: [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/)

> “In the model, there were three states of health: progression-free survival (PFS), progressed disease (PD), and death.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

<a id="topic-4.2.2-1"></a>

##### Budget impact model of ficerafusp alfa: perspective and time frame

No evidence found.

<a id="topic-4.2.2-2"></a>

##### Perspective recommended for budget impact analysis

> “The Task Force recommends that the budget impact of a new health technology should consider the perspective of the specific health-care decision-maker.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

> “In either case, the BIA should use data that reflect values specific to a particular decision maker's population.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

<a id="topic-4.2.2-3"></a>

##### Perspectives and time horizons of United States cost-effectiveness analyses of first-line regimens

> “A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

> “The purpose of this study was to compare the cost-effectiveness of nivolumab plus ipilimumab with EXTREME in the first-line setting from the standpoint of third-party payers in the United States.”
> “The projecting of costs and outcomes over 15 years was done using a three-state partitioned survival model discounted by 3% per year.”
> “The time horizon was 15 years given that more than 98% of the cohort died.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

##### Budget impact model of ficerafusp alfa: eligible population inputs

No evidence found.

<a id="topic-4.2.3-2"></a>

##### Estimated new cases and deaths in the United States in 2026 by head and neck site

| Site | Estimated new cases, both sexes | Estimated deaths, both sexes |
| --- | --- | --- |
| Oral cavity and pharynx | “60,480” | “13,150” |
| Tongue | “20,420” | “3,560” |
| Mouth | “15,810” | “3,340” |
| Pharynx | “21,760” | “4,760” |
| Other oral cavity | “2,490” | “1,490” |
| Larynx | “12,290” | “3,960” |

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-4.2.3-3"></a>

##### Oral cavity and pharynx cancer incidence in the United States

> “In 2026, it is estimated that there will be 60,480 new cases of oral cavity and pharynx cancer and an estimated 13,150 people will die of this disease.”
> “The rate of new cases of oral cavity and pharynx cancer was 11.7 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-4.2.3-4"></a>

##### Laryngeal cancer incidence in the United States

> “In 2026, it is estimated that there will be 12,290 new cases of laryngeal cancer and an estimated 3,960 people will die of this disease.”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-4.2.3-5"></a>

##### Stage at diagnosis of oral cavity and pharynx cancer

| Stage at diagnosis | Percent of cases |
| --- | --- |
| Localized (confined to primary site) | “26%” |
| Regional (spread to regional lymph nodes) | “55%” |
| Distant (cancer has metastasized) | “12%” |
| Unknown (unstaged) | “6%” |

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-4.2.3-6"></a>

##### Stage at diagnosis of laryngeal cancer

| Stage at diagnosis | Percent of cases |
| --- | --- |
| Localized (confined to primary site) | “49%” |
| Regional (spread to regional lymph nodes) | “30%” |
| Distant (cancer has metastasized) | “15%” |
| Unknown (unstaged) | “6%” |

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-4.2.3-7"></a>

##### Share of head and neck cancer of squamous cell origin and share presenting with or progressing to recurrent or metastatic disease

> “Head and neck cancer accounts for approximately 4% of all cancers in the U.S. with over 90% of cases presenting with squamous cell origin.”
> “At the time of diagnosis, an estimated 10% of patients have metastatic disease, and up to 30% of additional patients develop a recurrence or metastases over time after initial treatment for advanced HNSCC.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-4.2.3-8"></a>

##### Recurrence among older patients with locoregionally advanced disease in SEER-Medicare

> “In the resected group (n = 502), 333 patients experienced recurrence and had a 63% increased risk of death vs nonrecurrent patients”
> “In those unresected (n = 1,217), 791 patients experienced recurrence and had a 77% increased risk of death”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-4.2.3-9"></a>

##### Share of recurrent or metastatic disease that is HPV-negative

> “An estimated 80% of cases of R/M HNSCC are HPV-negative, with testing for HPV status typically only being conducted in tumors originating from the oropharynx.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

> “In this cohort, 60.4% of patients had non-HPV associated disease, 32.6% had HPV-associated disease, and 7.0% had unknown HPV status or primary tumor site.”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/)

<a id="topic-4.2.3-10"></a>

##### Share of oropharyngeal squamous cell carcinoma attributable to HPV in the United States

| Measure, oropharynx, 2012 to 2016 | Value |
| --- | --- |
| Reported HPV-associated cancers, average annual number | “19,000” |
| Attributable to 9vHPV-targeted types, number (%) | “12,600 (66)” |
| Attributable to other HPV types, number (%) | “900 (5)” |
| HPV-negative, number (%) | “5,500 (29)” |

Source: [Senkomago et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6705893/)

<a id="topic-4.2.3-11"></a>

##### HPV status and PD-L1 expression in the first-line pembrolizumab trial population

> “Twenty-two percent of patients’ tumors were HPV-positive, 23% had PD-L1 TPS ≥50%, and 95% had Stage IV disease”
> “Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

> “Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19.”

Source: [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-4.2.3-12"></a>

##### PD-L1 testing before first-line therapy in United States practice

> “Of 2,207 patients, 32.7 % received PD-L1 testing before 1L therapy initiation, 17.4 % after 1L therapy initiation, and 50.0 % were never tested.”

Source: [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/)

<a id="topic-4.2.3-13"></a>

##### First-line treatment mix and receipt of later lines in United States practice

> “1410 patients (54.7%) were treated with anti-PD1 monotherapy, 577 (22.4%) with combination anti-PD1 plus chemotherapy, and 590 (22.9%) with cetuximab plus chemotherapy in the front-line setting for recurrent or metastatic disease.”
> “Out of 2577 patients, 1128 patients (43.8%) were reported to have received second line treatment”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/)

<a id="topic-4.2.3-14"></a>

##### Company estimate of newly diagnosed HPV-negative patients in the United States

> “HPV-negative patients newly diagnosed each year in the US, EU5 and Japan”
> “of those patients in the US alone”
> “Tessellon patient flow modeling; SEER; country-specific registries; literature review.”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

##### Budget impact model of ficerafusp alfa: cost assumptions

No evidence found.

<a id="topic-4.2.4-2"></a>

##### Ficerafusp alfa price

No evidence found.

<a id="topic-4.2.4-3"></a>

##### Ficerafusp alfa dose and schedule in the pivotal trial

> “1500mg dosed once weekly, or QW, of ficerafusp alfa in combination with pembrolizumab”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-4.2.4-4"></a>

##### Pembrolizumab list price

> “for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44.”
> “The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $25,034.88.”
> “The list price is also referred to as wholesale acquisition cost or WAC.”
> “The list price does not include other treatment-related costs. The list price is current as of September 2026.”

Source: [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/)

<a id="topic-4.2.4-5"></a>

##### Pembrolizumab dose and maximum treatment duration

> “HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.”
> “Treatment with KEYTRUDA continued until RECIST v1.1-defined progression of disease as determined by the investigator, unacceptable toxicity, or a maximum of 24 months.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-4.2.4-6"></a>

##### Real-world time on first-line pembrolizumab treatment

> “The median (95% CI) rwToT for the monotherapy group was 4.2 (3.5–4.6) months, while the median (95% CI) rwTTNT was 6.5 (5.4–7.4) months”
> “The median rwToTs observed in the current study were also numerically similar to the corresponding median durations of study therapy observed in KEYNOTE-048 (4.2 versus 3.5 months for pembrolizumab monotherapy and 4.9 versus 5.8 months for pembrolizumab plus chemotherapy)”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

<a id="topic-4.2.4-7"></a>

##### Cetuximab list price

> “The list price1 of Erbitux is $17,235.60 per month, but the amount you pay will largely depend on your insurance plan.”
> “The dosing and pricing assumptions for a monthly supply of Erbitux are based on an average-sized patient by indication.”

Source: [Lilly ERBITUX cost information (2026)](https://www.lillypricinginfo.com/erbitux)

<a id="topic-4.2.4-8"></a>

##### Cetuximab dose with chemotherapy

> “Weekly: Administer initial dose of 400 mg/m2 as a 120-minute intravenous infusion, and subsequent doses of 250 mg/m2 infused over 60 minutes once weekly.”
> “Biweekly: Administer 500 mg/m2 as a 120-minute intravenous infusion every two weeks.”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-4.2.4-9"></a>

##### United States unit drug, administration, and terminal care costs used in a first-line cost-effectiveness model

| Input | Value (95% CI) |
| --- | --- |
| Nivolumab, drug cost per 1 mg, $ | “30 (29–32)” |
| Cisplatin, drug cost per 1 mg, $ | “0.17 (0.14–0.2)” |
| Carboplatin, drug cost per 1 mg, $ | “0.05 (0.04–0.06)” |
| Fluorouracil, drug cost per 1 mg, $ | “0.005 (0.004–0.006)” |
| Cetuximab, drug cost per 1 mg, $ | “7.04 (5.63–8.44)” |
| Terminal care cost per patient, $ | “11,126 (8901–13,351)” |
| Best supportive care cost per cycle, $ | “4645 (3716–5574)” |
| Drug administration, first hour, $ | “150.34 (123.55–198.06)” |
| Drug administration, additional hour, $ | “32.23 (27.29–41.02)” |

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

<a id="topic-4.2.4-10"></a>

##### Cost categories in a first-line cost-effectiveness model of pembrolizumab regimens

> “Costs included first-line and subsequent treatments, disease management, adverse events, and terminal care costs.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

<a id="topic-4.2.4-11"></a>

##### Incremental monthly health care costs associated with recurrence

> “Recurrence was associated with higher HCRU and monthly health care costs in both resected ($3,831; 95% CI = $2,319-$5,360) and unresected ($4,730; 95% CI = $3,611-$5,870) groups (P < 0.001).”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

Additional sources: [Haddad et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31928375/)

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

<a id="topic-4.2.5-1"></a>

##### Budget impact model of ficerafusp alfa: model outcomes

No evidence found.

<a id="topic-4.2.5-2"></a>

##### Outcomes recommended for budget impact analysis

> “The outcomes of the BIA should be presented in the format of interest to health care decision makers.”
> “In a computer program, options should be provided for different categories of costs to be included or excluded from the analysis.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “If a health condition model is needed for the BIA, it should reflect health outcomes and their related costs in the total affected population for each year after the new intervention is introduced into clinical practice.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.5-3"></a>

##### Outcomes reported by United States cost-effectiveness analyses of first-line regimens

> “Total cost, health outcomes, and incremental cost-effective ratios (ICERs) were estimated.”

Source: [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/)

> “The incremental net health benefit (INHB), incremental net monetary benefit (INMB), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) were calculated.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

> “Utilities were derived from the KEYNOTE-048 Euro-QoL five-dimension data and using a US algorithm.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

<a id="topic-4.2.6.1-1"></a>

###### Budget impact model of ficerafusp alfa: base-case results

No evidence found.

<a id="topic-4.2.6.1-2"></a>

###### Base-case results for first-line pembrolizumab regimens

> “In the CPS ≥1 R/M HNSCC population, pembrolizumab monotherapy was dominant vs. EXTREME and TPEx regimens, and cost-effective (at $100,000/QALY threshold) vs. platinum+5-FU ($86,827/QALY) and cisplatin + paclitaxel ($81,473/QALY).”
> “Pembrolizumab combination therapy in the overall R/M HNSCC population was dominant vs. TPEx regimen, and cost-effective vs. EXTREME regimen ($1769/QALY), platinum+5-FU ($81,989/QALY), and cisplatin + paclitaxel ($89,505/QALY).”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

<a id="topic-4.2.6.1-3"></a>

###### Base-case results for first-line pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy

> “When compared with cetuximab plus chemotherapy, the pembrolizumab monotherapy strategy was dominated by lower cost and better efficacy in all three populations.”
> “The incremental costs and quality adjusted life years (QALYs) yielded by pembrolizumab plus chemotherapy compared with cetuximab plus chemotherapy were $16016.88 and 0.11 in the total population, and $24467.47 and 0.18 and $30448.46 and 0.20 in the populations with a PD-L1 CPS ≥ 1 and CPS ≥ 20, respectively, leading to ICERs of $147876.14, $134237.84, and $153660.78 per QALY, respectively.”

Source: [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/)

<a id="topic-4.2.6.1-4"></a>

###### Base-case results for first-line nivolumab plus ipilimumab versus the EXTREME regimen

| Base-case result, overall population | EXTREME | Nivolumab plus ipilimumab | Incremental change |
| --- | --- | --- | --- |
| Drug cost, $ | “290,970” | “322,595” | “− 31,625” |
| Nondrug cost, $ | “565,153” | “532,956” | “32,197” |
| Overall cost, $ | “856,123” | “855,551” | “572” |
| QALYs | “1.747” | “1.671” | “0.076” |
| ICER per QALY, $ | “NA” | “NA” | “7545” |

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

<a id="topic-4.2.6.2-1"></a>

###### Budget impact model of ficerafusp alfa: scenario analyses

No evidence found.

<a id="topic-4.2.6.2-2"></a>

###### Scenario and sensitivity analyses recommended for budget impact analysis

> “Sensitivity analysis should be of alternative scenarios chosen from the perspective of the decision maker.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “The Task Force recommends that budget impact analyses be generated as a series of scenario analyses in the same manner that sensitivity analyses would be provided for CEAs.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.6.2-3"></a>

###### Sensitivity analyses in United States cost-effectiveness analyses of first-line regimens

> “Sensitivity analyses showed a high cost-effectiveness probability for pembrolizumab at the $100,000/QALY threshold.”

Source: [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)

> “Variations in HR for OS and body weight were generally the strongest influences on ICERs.”
> “Given a WTP threshold of $150,000 per QALY, the probability of the EXTREME regiment being cost-effective compared with nivolumab and ipilimumab, was 64%.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

##### Summary

Task force good-practice guidance on budget impact analysis lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker, data from the decision maker's own population where possible, and presentation as a series of scenario analyses. For ficerafusp alfa, two inputs are not yet available: a price, and efficacy from randomized evidence. Results reported to date come from a nonrandomized, open-label phase 1/1b trial, and Bicara expects an interim analysis of the randomized FORTIFI-HN01 trial in mid-2027.

The population inputs in this report differ by source and are candidates for scenario ranges. The estimated HPV-negative share of recurrent or metastatic disease is 80% in Bicara's Form 10-K; in a U.S. real-world first-line cohort, 60.4% had non-HPV associated disease and 7.0% had unknown HPV status or primary site, and in a U.S. real-world cohort of first-line pembrolizumab recipients, 258 participants (39.9%) were HPV-negative and 155 (24.0%) equivocal or unknown. Bicara states that up to 30% of patients develop a recurrence or metastases after initial treatment for advanced HNSCC; Hanna et al. (2026) state that approximately 50% of those with locally advanced HNSCC have recurrence or metastasis after initial therapy; of 2,207 U.S. participants, 32.7%. Because the pivotal population requires PD-L1 CPS ≥1, testing rates bear on the identifiable population: of 2,207 U.S. participants, 32.7% received PD-L1 testing before first-line therapy and 50.0% were never tested.

On costs, pembrolizumab is given in both arms of FORTIFI-HN01, and ficerafusp alfa is given weekly until disease progression or unacceptable toxicity, while pembrolizumab is given for up to 35 cycles. FORTIFI-FLEX is evaluating a 12-week loading phase of 1500 mg weekly followed by 2250 mg every 3 weeks, which would change the number of administrations if adopted. Bicara states that third-party payers “may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/); [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/); [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/); [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/); [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129); [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-4.2.7-2"></a>

##### Company statements on pricing, coverage, and reimbursement of ficerafusp alfa

> “Even if ficerafusp alfa achieves marketing approval, it may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.”
> “The availability of coverage and the adequacy of reimbursement by governmental healthcare programs including but not limited to Medicare and Medicaid, private health insurers and other third-party payors, are essential for most patients to be able to afford prescription medications such as ficerafusp alfa or any future product candidates, if approved.”
> “Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-4.2.7-3"></a>

##### Data sources recommended for budget impact inputs

> “Data sources for the BIA should include published clinical trial estimates and comparator studies for the efficacy and safety of the current and new interventions as well as the decision maker's own population for the other parameter estimates, where possible.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
